Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic

Imperiale, 2003, Aspirin and the prevention of colorectal cancer, N Engl J Med, 348, 879, 10.1056/NEJMp030005 Koehne, 2004, COX-2 inhibition and colorectal cancer, Semin Oncol, 31, 12, 10.1053/j.seminoncol.2004.03.041 Khuder, 2001, Breast cancer and NSAIDs use: a metaanalysis, Br J Cancer, 84, 1188, 10.1054/bjoc.2000.1709 Castelao, 2000, Non steroidal anti-inflammatory drugs and bladder cancer prevention, Br J Cancer, 82, 1364, 10.1054/bjoc.1999.1106 Irani, 2002, Effect of non steroidal anti-inflammatory agents and finasteride on prostate cancer risk, J Urol, 168, 1985, 10.1016/S0022-5347(05)64277-2 Harris, 2002, Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers, Oncol Rep, 9, 693 Muscat, 2003, Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs, Cancer, 97, 1732, 10.1002/cncr.11242 Lands, 1979, The biosynthesis and metabolism of prostaglandins, Annu Rev Physiol, 41, 633, 10.1146/annurev.ph.41.030179.003221 Merlie, 1988, Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase), J Biol Chem, 263, 3550, 10.1016/S0021-9258(18)68959-8 DeWitt, 1988, Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence, Proc Natl Acad Sci USA, 85, 1412, 10.1073/pnas.85.5.1412 Yokoyama, 1988, Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence, FEBS Lett, 231, 347, 10.1016/0014-5793(88)80847-0 Xie, 1991, Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing, Proc Natl Acad Sci USA, 88, 2692, 10.1073/pnas.88.7.2692 Chandrasekharan, 2002, COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression, Proc Natl Acad Sci USA, 15, 13926, 10.1073/pnas.162468699 Josephy, 1989, Prostaglandin H synthase-dependent mutagenic activation of benzidine in a Salmonella typhimurium Ames tester strain possessing elevated N-acetyltransferase levels, Cancer Res, 15, 853 Smith, 2000, Cyclooxygenases: structural, cellular, and molecular biology, Annu Rev Biochem, 69, 145, 10.1146/annurev.biochem.69.1.145 Herschman, 1996, Prostaglandin synthase 2, Biochim Biophys Acta, 5, 125, 10.1016/0005-2760(95)00194-8 Dubois, 1998, Cyclooxygenase in biology and disease, FASEB J, 12, 1063, 10.1096/fasebj.12.12.1063 Herschman, 1995, Inflammation, reproduction, cancer and all that …. The regulation and role of the inducible prostaglandin synthase, Bioessays, 17, 1031, 10.1002/bies.950171207 Kage, 1999, Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone, Biochem Biophys Res Commun, 254, 259, 10.1006/bbrc.1998.9875 Fong, 2000, TGF-beta1 stimulates IL-8 release, COX-2 expression, and PGE(2) release in human airway smooth muscle cells, Am J Physiol Lung Cell Mol Physiol, 279, L201, 10.1152/ajplung.2000.279.1.L201 Saha, 1999, Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells, Neoplasia, 1, 508, 10.1038/sj.neo.7900051 Diaz, 1998, Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts, Exp Cell Res, 241, 222, 10.1006/excr.1998.4050 Kosaka, 1994, Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2, Eur J Biochem, 221, 889, 10.1111/j.1432-1033.1994.tb18804.x Tanabe, 2002, Cyclooxygenase isozymes and their gene structures and expression, Prostaglandins Other Lipid Mediat, 68–69, 95, 10.1016/S0090-6980(02)00024-2 Iniguez, 2000, An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes, J Biol Chem, 275, 23627, 10.1074/jbc.M001381200 Liu, 2004, Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells, J Biol Chem, 279, 18694, 10.1074/jbc.M308136200 Miller, 1998, Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: co-stimulation of AP-1 and CRE nuclear binding proteins, J Cell Biochem, 69, 392, 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.0.CO;2-I Morham, 1995, Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse, Cell, 83, 473, 10.1016/0092-8674(95)90125-6 Bombardier, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group, N Engl J Med, 343, 1520, 10.1056/NEJM200011233432103 Nussmeier, 2005, Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery, N Engl J Med, 352, 1081, 10.1056/NEJMoa050330 Silverstein, 2000, Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study, JAMA, 284, 1247, 10.1001/jama.284.10.1247 Bjorkman, 1998, The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins, Am J Med, 105, 8S, 10.1016/S0002-9343(98)00069-2 Kato, 2001, Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes, J Pharm Pharmacol, 53, 1679, 10.1211/0022357011778070 Warner, 1999, Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc Natl Acad Sci USA, 96, 7563, 10.1073/pnas.96.13.7563 Patrignani, 1997, Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs, J Physiol Pharmacol, 48, 623 Arico, 2002, Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line, J Biol Chem, 277, 27613, 10.1074/jbc.M201119200 Dannenberg, 2001, Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer, Lancet Oncol, 2, 544, 10.1016/S1470-2045(01)00488-0 Wang, 2006, Prostaglandins and cancer, Gut, 55, 115, 10.1136/gut.2004.047100 Hull, 2005, Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?, Eur J Cancer, 41, 1854, 10.1016/j.ejca.2005.04.013 Oshima, 1995, Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene, Proc Natl Acad Sci USA, 92, 4482, 10.1073/pnas.92.10.4482 Oshima, 1996, Suppression of intestinal polyposis in Apc delta716 knock-out mice by inhibition of cyclooxygenase 2 (COX-2), Cell, 87, 803, 10.1016/S0092-8674(00)81988-1 Moser, 1990, A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse, Science, 247, 322, 10.1126/science.2296722 Shoemaker, 1997, Studies of neoplasia in the Min mouse, Biochim Biophys Acta, 1332, F25 Chulada, 2000, Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice, Cancer Res, 60, 4705 Liu, 2001, Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice, J Biol Chem, 276, 18563, 10.1074/jbc.M010787200 Seed, 1997, The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan, Cancer Res, 57, 1625 Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 9, 669, 10.1038/nm0603-669 Kuwashima, 1988, Stimulation of endothelial cell prostacyclin release by retina-derived factors, Invest Ophthalmol Vis Sci, 29, 1213 Murohara, 1998, Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin, Circulation, 97, 99, 10.1161/01.CIR.97.1.99 Liu, 2002, Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line, J Biol Chem, 277, 50081, 10.1074/jbc.M201095200 Krysan, 2005, Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner, Cancer Res, 65, 6275, 10.1158/0008-5472.CAN-05-0216 Cheng, 1998, Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells, Invest Ophthalmol Vis Sci, 39, 581 Amano, 2003, Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth, J Exp Med, 197, 221, 10.1084/jem.20021408 Tsujii, 1998, Cyclooxygenase regulates angiogenesis induced by colon cancer cells, Cell, 93, 705, 10.1016/S0092-8674(00)81433-6 Williams, 2000, Host cyclooxygenase-2 modulates carcinoma growth, J Clin Invest, 105, 1589, 10.1172/JCI9621 Lim, 2003, Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma, Oncol Rep, 10, 1241 Timoshenko, 2006, COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer, Br J Cancer, 94, 1154, 10.1038/sj.bjc.6603067 Masferrer, 2000, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res, 60, 1306 Brueggemeier, 1999, Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens, Cancer Lett, 140, 27, 10.1016/S0304-3835(99)00050-6 Karuppu, 2002, Aromatase and prostaglandin inter-relationships in breast adipose tissue: significance for breast cancer development, Breast Cancer Res Treat, 76, 103, 10.1023/A:1020531329686 Sheng, 2001, Prostaglandin E2 increases growth and motility of colorectal carcinoma cells, J Biol Chem, 276, 18075, 10.1074/jbc.M009689200 Tsujii, 1997, Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential, Proc Natl Acad Sci USA, 94, 3336, 10.1073/pnas.94.7.3336 Singh, 2005, COX-2 overexpression increases motility and invasion of breast cancer cells, Int J Oncol, 26, 1393 Davis, 2004, Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature, Cancer Res, 64, 279, 10.1158/0008-5472.CAN-03-1168 Terakado, 2004, Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma, Oral Oncol, 40, 383, 10.1016/j.oraloncology.2003.09.005 Shin, 2005, Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels, Cancer Res, 65, 9501, 10.1158/0008-5472.CAN-05-0220 Reed, 1999, Dysregulation of apoptosis in cancer, J Clin Oncol, 17, 2941, 10.1200/JCO.1999.17.9.2941 Campos, 1993, High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy, Blood, 81, 3091, 10.1182/blood.V81.11.3091.3091 Bargou, 1995, Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis, Int J Cancer, 60, 854, 10.1002/ijc.2910600622 Prokop, 2000, Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo, Leukemia, 14, 1606, 10.1038/sj.leu.2401866 Sturm, 1999, Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases, J Clin Oncol, 17, 1364, 10.1200/JCO.1999.17.5.1364 Lima, 2004, Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells, Cancer Gene Ther, 11, 309, 10.1038/sj.cgt.7700706 Zangemeister-Wittke, 2003, Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling, Ann N Y Acad Sci, 1002, 90, 10.1196/annals.1281.019 Nita, 1998, 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins, Br J Cancer, 78, 986, 10.1038/bjc.1998.617 Liu, 1998, NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells, Cancer Res, 58, 4245 Zhang, 2000, Role of BAX in the apoptotic response to anticancer agents, Science, 290, 989, 10.1126/science.290.5493.989 Zhou, 2001, Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak, Carcinogenesis, 22, 1393, 10.1093/carcin/22.9.1393 Ding, 2005, Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9, Int J Cancer, 113, 803, 10.1002/ijc.20639 Narayanan, 2003, Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s), Clin Cancer Res, 9, 3503 Gajewski, 1996, Apoptosis meets signal transduction: elimination of a BAD influence, Cell, 87, 589, 10.1016/S0092-8674(00)81377-X Cardone, 1998, Regulation of cell death protease caspase-9 by phosphorylation, Science, 282, 1318, 10.1126/science.282.5392.1318 Hsu, 2000, The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2, J Biol Chem, 275, 11397, 10.1074/jbc.275.15.11397 Basu, 2004, Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer, Mol Cancer Res, 2, 632, 10.1158/1541-7786.632.2.11 Zhang, 2004, Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation, Hepatology, 39, 1028, 10.1002/hep.20143 Wu, 2004, The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells, Mol Cancer Ther, 3, 299, 10.1158/1535-7163.299.3.3 Lin, 2001, Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway, J Biol Chem, 276, 48997, 10.1074/jbc.M107829200 Adida, 2000, Expression and prognostic significance of survivin in de novo acute myeloid leukaemia, Br J Haematol, 111, 196, 10.1046/j.1365-2141.2000.02328.x Adida, 1998, Anti-apoptosis gene, survivin, and prognosis of neuroblastoma, Lancet, 351, 882, 10.1016/S0140-6736(05)70294-4 Li, 2001, Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins, Endocrinology, 142, 370, 10.1210/en.142.1.370 Datta, 2000, XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage, J Biol Chem, 275, 31733, 10.1074/jbc.M910231199 Nishihara, 2003, Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2, Proc Natl Acad Sci USA, 100, 8921, 10.1073/pnas.1533221100 Krysan, 2004, COX-2-dependent stabilization of survivin in non-small cell lung cancer, FASEB J, 18, 206, 10.1096/fj.03-0369fje Krysan, 2004, Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer, Cancer Res, 64, 6359, 10.1158/0008-5472.CAN-04-1681 Zhang, 2004, The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells, J Pharmacol Exp Ther, 308, 434, 10.1124/jpet.103.059378 Shishodia, 2004, Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis, J Biol Chem, 279, 47148, 10.1074/jbc.M408093200 Wang, 1999, Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB, Nat Med, 5, 412, 10.1038/10577 Guo, 2004, Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit, Clin Cancer Res, 10, 3333, 10.1158/1078-0432.CCR-03-0366 Kopp, 1994, Inhibition of NF-kappa B by sodium salicylate and aspirin, Science, 265, 956, 10.1126/science.8052854 Yin, 1998, The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta, Nature, 396, 77, 10.1038/23948 Yamamoto, 1999, Sulindac inhibits activation of the NF-kappaB pathway, J Biol Chem, 274, 27307, 10.1074/jbc.274.38.27307 Wong, 2003, Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer, Oncogene, 22, 1189, 10.1038/sj.onc.1206234 Shishodia, 2004, Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis, J Immunol, 173, 2011, 10.4049/jimmunol.173.3.2011 Duffy, 1998, Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs), Eur J Cancer, 34, 1250, 10.1016/S0959-8049(98)00045-8 Kang, 2005, Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells, Mol Cancer Ther, 4, 1358, 10.1158/1535-7163.MCT-05-0139 Puhlmann, 2005, Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells, J Pharmacol Exp Ther, 312, 346, 10.1124/jpet.104.071571 O’Connor, 2004, Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer, Anticancer Res, 24, 457 Mizutani, 2004, Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522, J Urol, 172, 1474, 10.1097/01.ju.0000131945.74377.ad Lin, 2005, Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells, Biochem Pharmacol, 70, 658, 10.1016/j.bcp.2005.05.028 Czembirek, 2005, Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines, Oncol Rep, 14, 1523 Vadlamudi, 1999, Regulation of cyclooxygenase-2 pathway by HER2 receptor, Oncogene, 18, 305, 10.1038/sj.onc.1202307 Subbaramaiah, 2000, Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3, J Biol Chem, 277, 18649, 10.1074/jbc.M111415200 Wang, 2004, Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2, Cancer Cell, 6, 251, 10.1016/j.ccr.2004.07.012 Mann, 2001, Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth, Gastroenterology, 120, 1713, 10.1053/gast.2001.24844 Olayioye, 2000, The ErbB signaling network: receptor heterodimerization in development and cancer, EMBO J, 19, 3159, 10.1093/emboj/19.13.3159 Yarden, 2001, The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities, Eur J Cancer, 37, S3, 10.1016/S0959-8049(01)00230-1 Buchanan, 2003, Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor, J Biol Chem, 278, 35451, 10.1074/jbc.M302474200 Pai, 2002, Prostaglandin E2 transactivates EGF receptor a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy, Nat Med, 8, 289, 10.1038/nm0302-289 Dannenberg, 2005, Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention, J Clin Oncol, 23, 254, 10.1200/JCO.2005.09.112 Shao, 2003, Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin, Cancer Res, 63, 5218 Özören, 2003, Cell surface death receptor signaling in normal and cancer cells, Semin Cancer Biol, 13, 135, 10.1016/S1044-579X(02)00131-1 de Jong, 2001, Death receptor ligands, in particular TRAIL, to overcome drug resistance, Cancer Metastasis Rev, 20, 51, 10.1023/A:1013112624971 Hengartner, 2000, The biochemistry of apoptosis, Nature, 407, 770, 10.1038/35037710 Zhang, 2004, Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation, Hepatology, 39, 1028, 10.1002/hep.20143 Han, 2001, A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line, J Biol Chem, 276, 38748, 10.1074/jbc.M106214200 de Groot, 2005, Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells, Br J Cancer, 92, 1459, 10.1038/sj.bjc.6602516 Cheng, 2003, Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells, Int J Oncol, 23, 113 Liu, 2004, Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells, J Natl Cancer Inst, 96, 1769, 10.1093/jnci/djh322 Huang, 2001, Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells, Cancer Res, 61, 6918 Martin, 2005, Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae, Cancer Res, 65, 11447, 10.1158/0008-5472.CAN-05-1494 He, 2002, Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells, Oncogene, 21, 6032, 10.1038/sj.onc.1205897 Huang, 2001, Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells, Cancer Res, 61, 6918 Tang, 2002, Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells, Cancer Res, 62, 4903 Ravi, 2002, Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L), Cancer Res, 62, 1583 Teicher, 1994, Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies, Cancer Chemother Pharmacol, 33, 515, 10.1007/BF00686511 Hattori, 2001, Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth, Biol Pharm Bull, 24, 1214, 10.1248/bpb.24.1214 Matsushita, 2001, Synergistic effect of indomethacin and bleomycin on tumor growth produced by activating antitumor immunity, Pharm Res, 18, 243, 10.1023/A:1011048905732 Yao, 2003, Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice, Cancer Res, 63, 586 Lala, 1990, Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ, Int Immunol, 2, 1149, 10.1093/intimm/2.12.1149 Knapp, 2000, Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer, Cancer Chemother Pharmacol, 46, 221, 10.1007/s002800000147 Hayashi, 2001, Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm, Hepatology, 34, 638, 10.1053/jhep.2001.28198 Howe, 2001, Cyclooxygenase-2: a target for the prevention and treatment of breast cancer, Endocr Relat Cancer, 8, 97, 10.1677/erc.0.0080097 Kagoura, 2001, Immunohistochemical expression of cyclooxygenase-2 in skin cancers, J Cutan Pathol, 28, 298, 10.1034/j.1600-0560.2001.028006298.x Kulkarni, 2001, Cyclooxygenase-2 is overexpressed in human cervical cancer, Clin Cancer Res, 7, 429 Marrogi, 2000, Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor, Cancer Res, 60, 3696 Chan, 1999, Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck, Cancer Res, 59, 991 Shiota, 1999, Cyclooxygenase-2 expression in hepatocellular carcinoma, Hepatogastroenterology, 46, 407 Wolff, 1998, Expression of cyclooxygenase-2 in human lung carcinoma, Cancer Res, 58, 4997 Tucker, 1999, Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer, Cancer Res, 59, 987 Uefuji, 2001, Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas, J Surg Oncol, 76, 26, 10.1002/1096-9098(200101)76:1<26::AID-JSO1005>3.0.CO;2-A Zimmermann, 1999, Cyclooxygenase-2 expression in human esophageal carcinoma, Cancer Res, 59, 198 Kondo, 1999, Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma, Clin Cancer Res, 5, 4005 Mohammed, 1999, Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder, Cancer Res, 59, 5647 Tong, 2000, Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma, Neoplasia, 2, 483, 10.1038/sj.neo.7900119 Muller-Decker, 1999, Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin, Int J Cancer, 82, 648, 10.1002/(SICI)1097-0215(19990827)82:5<648::AID-IJC6>3.0.CO;2-D Yoshimura, 2000, Expression of cyclooxygenase-2 in prostate carcinoma, Cancer, 89, 589, 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C Fujita, 1998, Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas, Cancer Res, 58, 4823 Sheehan, 1999, The relationship between cyclooxygenase-2 expression and colorectal cancer, JAMA, 282, 1254, 10.1001/jama.282.13.1254 Koki, 2002, Celecoxib: a specific COX-2 inhibitor with anticancer properties, Cancer Contr, 9, 28, 10.1177/107327480200902S04 Shirahama, 2001, Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder, Cancer, 92, 188, 10.1002/1097-0142(20010701)92:1<188::AID-CNCR1308>3.0.CO;2-W Achiwa, 1999, Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas, Clin Cancer Res, 5, 1001 Khuri, 2001, Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer, Clin Cancer Res, 7, 861 Eberhart, 1994, Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas, Gastroenterology, 107, 1183, 10.1016/0016-5085(94)90246-1 Takahashi, 2002, Increased expression of COX-2 in the development of human lung cancers, J Environ Pathol Toxicol Oncol, 21, 177, 10.1615/JEnvironPatholToxicolOncol.v21.i2.110 Hase, 2003, Cyclooxygenase-1 and -2 in human testicular tumours, Eur J Cancer, 39, 2043, 10.1016/S0959-8049(03)00485-4 Morris, 2001, Cyclooxygenase-2 expression in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence, Am J Gastroenterol, 96, 990 Wilson, 1998, Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas, Cancer Res, 58, 2929 Saukkonen, 2003, Cyclooxygenase-2 and gastric carcinogenesis, APMIS, 111, 915, 10.1034/j.1600-0463.2003.1111001.x Sung, 2000, Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions, Am J Pathol, 157, 729, 10.1016/S0002-9440(10)64586-5 Shirahama, 2000, Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder, Clin Cancer Res, 6, 2424 Buckman, 1998, COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer, Carcinogenesis, 19, 723, 10.1093/carcin/19.5.723 Hosomi, 2000, Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung, Lung Cancer, 30, 73, 10.1016/S0169-5002(00)00132-X Ohno, 2001, Depth of invasison parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma, Cancer, 91, 1876, 10.1002/1097-0142(20010515)91:10<1876::AID-CNCR1209>3.0.CO;2-H Murata, 1999, Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma, Am J Gastroenterol, 94, 451, 10.1111/j.1572-0241.1999.876_e.x Lim, 2000, Increased expression of cyclooxygenase-2 protein in human gastric carcinoma, Clin Cancer Res, 6, 519 Fujita, 1998, Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas, Cancer Res, 58, 4823 Sheehan, 1999, The relationship between cyclooxygenase-2 expression and colorectal cancer, JAMA, 282, 1254, 10.1001/jama.282.13.1254 Chen, 2001, Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac, Int J Cancer, 91, 894, 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO;2-# Denkert, 2003, Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma, Cancer, 97, 2978, 10.1002/cncr.11437 Ristimaki, 2002, Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer, Cancer Res, 62, 632 Wulfing, 2003, Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis, J Cancer Res Clin Oncol, 129, 375, 10.1007/s00432-003-0459-1 Yuan, 2005, Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients, Int J Cancer, 115, 545, 10.1002/ijc.20898 Kim, 2003, Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer, Lung Cancer, 42, 163, 10.1016/S0169-5002(03)00290-3 Ferrandina, 2004, Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer, Clin Cancer Res, 10, 3117, 10.1158/1078-0432.CCR-1090-3 Chen, 2003, High cyclooxygenase-2 expression in cervical adenocarcinomas, Gynecol Oncol, 88, 379, 10.1016/S0090-8258(02)00066-5 Erkinheimo, 2004, Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma, Clin Cancer Res, 10, 538, 10.1158/1078-0432.CCR-0132-03 Gallo, 2002, Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma, Hum Pathol, 33, 708, 10.1053/hupa.2002.125376 Ranelletti, 2001, Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma, Int J Cancer, 95, 343, 10.1002/1097-0215(20011120)95:6<343::AID-IJC1060>3.0.CO;2-D Wulfing, 2004, Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy, Eur Urol, 45, 46, 10.1016/j.eururo.2003.08.007 Kim, 2002, Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer, Urology, 60, 816, 10.1016/S0090-4295(02)01909-X Soumaoro, 2004, Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer, Clin Cancer Res, 10, 8465, 10.1158/1078-0432.CCR-04-0653 Hull, 2000, Cyclooxygenase-2 expression in colorectal cancer liver metastases, Clin Exp Metastasis, 18, 21, 10.1023/A:1026553605636 Baldi, 2004, Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma, Thorax, 59, 428, 10.1136/thx.2003.008912 Edwards, 2002, Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma, Clin Cancer Res, 8, 1857 Buskens, 2002, Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus, Gastroenterology, 122, 1800, 10.1053/gast.2002.33580 Okano, 2004, Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome, Clin Cancer Res, 10, 6938, 10.1158/1078-0432.CCR-0731-03 Phillips, 2002, A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis, Gut, 50, 857, 10.1136/gut.50.6.857 Lundholm, 1994, Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors, Cancer Res, 54, 5602 Pruthi, 2004, A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy, BJU Int, 93, 275, 10.1111/j.1464-410X.2004.04601.x Ferrandina, 2003, Celecoxib modulates the expression of cyclooxygenase-2, Ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study, Clin Cancer Res, 9, 4324 Fenwick, 2003, The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases, Gastroenterology, 125, 716, 10.1016/S0016-5085(03)01061-8 Arber N. Chemoprevention of colorectal adenomas with celecoxib in an international randomized, placebo-controlled, double-blind trial. American Association for Cancer Research, abstract number CP-4; 2006. Bertagnolli MM, Eagle CJ, Hawk ET, The Adenoma Prevention with Celecoxib (APC) Study. Celecoxib reduces sporadic colorectal adenomas: results from the Adenoma Prevention with Celecoxib (APC) trial. American Association for Cancer Research, abstract number CP-3; 2006. Lin, 2002, Effect of celecoxib on capecitabine induced hand–foot syndrome and antitumor activity, Oncology (Huntingt), 16, 31 Kobayashi, 1999, The marked anticancer effect of combined VCR, MTX, and indomethacin against drug-resistant recurrent small cell lung carcinoma after conventional chemotherapy: report of a case, Surg Today, 29, 666, 10.1007/BF02482998 Altorki, 2003, Celecoxib a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer, J Clin Oncol, 21, 2645, 10.1200/JCO.2003.07.127 Chow, 2003, Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report, J Steroid Biochem Mol Biol, 86, 443, 10.1016/S0960-0760(03)00355-8 Dang, 2004, Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments, Clin Cancer Res, 10, 4062, 10.1158/1078-0432.CCR-03-0463 Becerra, 2003, Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study, Int J Cancer, 105, 868, 10.1002/ijc.11164 Spieth, 2003, Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study, Cancer Chemother Pharmacol, 52, 377, 10.1007/s00280-003-0678-9 Kohne, 2005, Capecitabine plus irinotecan versus 5-FU/FA/irinotecan±celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015, J Clin Oncol, 23, A-3252 Lin, 2002, Effect of celecoxib on capecitabine-induced hand–foot syndrome and antitumor activity, Oncology (Williston Park), 16, 31 Trifan, 2002, Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11, Cancer Res, 62, 5778 Gambaro, 2003, Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors, J Intern Med, 253, 643, 10.1046/j.1365-2796.2003.01146.x Laine, 2001, Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient, Gastroenterology, 120, 594, 10.1053/gast.2001.21907 Wolfe, 1999, Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs, N Engl J Med, 340, 1888, 10.1056/NEJM199906173402407 Bresalier, 2005, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 352, 1092, 10.1056/NEJMoa050493 Solomon, 2005, Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl J Med, 352, 1071, 10.1056/NEJMoa050405